BR112023006262A2 - Métodos de diagnóstico de tuberculose e de diferenciação entre tuberculose ativa e latente - Google Patents

Métodos de diagnóstico de tuberculose e de diferenciação entre tuberculose ativa e latente

Info

Publication number
BR112023006262A2
BR112023006262A2 BR112023006262A BR112023006262A BR112023006262A2 BR 112023006262 A2 BR112023006262 A2 BR 112023006262A2 BR 112023006262 A BR112023006262 A BR 112023006262A BR 112023006262 A BR112023006262 A BR 112023006262A BR 112023006262 A2 BR112023006262 A2 BR 112023006262A2
Authority
BR
Brazil
Prior art keywords
tuberculosis
methods
active
diagnosis
differentiation
Prior art date
Application number
BR112023006262A
Other languages
English (en)
Inventor
Nygren Malin
Original Assignee
Cepheid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cepheid filed Critical Cepheid
Publication of BR112023006262A2 publication Critical patent/BR112023006262A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9723—Urokinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

MÉTODOS DE DIAGNÓSTICO DE TUBERCULOSE E DE DIFERENCIAÇÃO ENTRE TUBERCULOSE ATIVA E LATENTE. São fornecidos composições e métodos para detectar infecção por Mycobacterium tuberculosis (MTB) em um paciente suspeito de estar infectado com Mycobacterium tuberculosis e para distinguir entre infecção por tuberculose ativa e latente. Os métodos também podem ser usados para monitorar a progressão da infecção por MTB ou para monitorar o tratamento de pacientes infectados por MTB. São utilizadas alterações no nível de expressão de genes para auxiliar no diagnóstico, prognóstico e tratamento da tuberculose.
BR112023006262A 2020-10-06 2021-10-05 Métodos de diagnóstico de tuberculose e de diferenciação entre tuberculose ativa e latente BR112023006262A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063088077P 2020-10-06 2020-10-06
US202063104187P 2020-10-22 2020-10-22
PCT/US2021/053594 WO2022076428A1 (en) 2020-10-06 2021-10-05 Methods of diagnosing tuberculosis and differentiating between active and latent tuberculosis

Publications (1)

Publication Number Publication Date
BR112023006262A2 true BR112023006262A2 (pt) 2023-05-09

Family

ID=78500726

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023006262A BR112023006262A2 (pt) 2020-10-06 2021-10-05 Métodos de diagnóstico de tuberculose e de diferenciação entre tuberculose ativa e latente

Country Status (6)

Country Link
US (1) US20220106627A1 (pt)
EP (1) EP4226158A1 (pt)
KR (1) KR20230080458A (pt)
CN (1) CN116348767A (pt)
BR (1) BR112023006262A2 (pt)
WO (1) WO2022076428A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368551B (zh) * 2015-10-14 2022-12-23 斯坦福大学托管董事会 用于诊断结核病的方法
BR112023006262A2 (pt) * 2020-10-06 2023-05-09 Cepheid Métodos de diagnóstico de tuberculose e de diferenciação entre tuberculose ativa e latente
CN114736276B (zh) * 2022-05-24 2023-08-01 中国人民解放军总医院第八医学中心 结核分枝杆菌ltbi-rd相关蛋白抗原的ctl表位肽及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449602A (en) 1988-01-13 1995-09-12 Amoco Corporation Template-directed photoligation
US5494810A (en) 1990-05-03 1996-02-27 Cornell Research Foundation, Inc. Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease
EP0920440B1 (en) 1996-02-09 2012-08-22 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
EP2369007B1 (en) 1996-05-29 2015-07-29 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US6312892B1 (en) 1996-07-19 2001-11-06 Cornell Research Foundation, Inc. High fidelity detection of nucleic acid differences by ligase detection reaction
US5958349A (en) 1997-02-28 1999-09-28 Cepheid Reaction vessel for heat-exchanging chemical processes
US6027998A (en) 1997-12-17 2000-02-22 Advanced Micro Devices, Inc. Method for fully planarized conductive line for a stack gate
ES2309022T3 (es) 1997-12-24 2008-12-16 Cepheid Dispositivo y procedimiento para lisis.
EP1144447B1 (en) 1998-11-04 2009-10-14 Isis Innovation Limited Tuberculosis diagnostic test
US6506594B1 (en) 1999-03-19 2003-01-14 Cornell Res Foundation Inc Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US6818185B1 (en) 1999-05-28 2004-11-16 Cepheid Cartridge for conducting a chemical reaction
DE60014676T2 (de) 1999-05-28 2005-11-17 Cepheid, Sunnyvale Vorrichtung und verfahren zur analyse flüssiger proben
US6403037B1 (en) 2000-02-04 2002-06-11 Cepheid Reaction vessel and temperature control system
AU2001265121A1 (en) 2000-05-30 2001-12-11 Applera Corporation Methods for detecting target nucleic acids using coupled ligation and amplification
US6605451B1 (en) 2000-06-06 2003-08-12 Xtrana, Inc. Methods and devices for multiplexing amplification reactions
GB0722105D0 (en) 2007-11-10 2007-12-19 Sec Dep For Environment Food A Antigens
ZA200905156B (en) * 2008-06-25 2010-05-26 South African Medical Res Council Marker for the rapid differentiation of active TB disease from latent tuberculosis infection
EP2791679A1 (en) * 2011-12-15 2014-10-22 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and kits for diagnosing latent tuberculosis infection
WO2013175459A2 (en) * 2012-05-25 2013-11-28 Stellenbosch University Method for diagnosing tuberculosis disease
GB201211158D0 (en) * 2012-06-22 2012-08-08 Univ Nottingham Trent Biomarkers and uses thereof
GB201213567D0 (en) * 2012-07-31 2012-09-12 Proteinlogic Ltd Biomarkers
US20150315643A1 (en) * 2012-12-13 2015-11-05 Baylor Research Institute Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
GB201401603D0 (en) * 2014-01-30 2014-03-19 Proteinlogic Ltd Biomarkers
US10295538B2 (en) 2014-08-15 2019-05-21 Oxford Immunotec Limited Mycobacterium tuberculosis proteins
CN108368551B (zh) * 2015-10-14 2022-12-23 斯坦福大学托管董事会 用于诊断结核病的方法
WO2017179008A1 (en) * 2016-04-15 2017-10-19 Stellenbosch University Host biomarkers for immunodiagnosis and monitoring of tuberculosis disease
BR112023006262A2 (pt) * 2020-10-06 2023-05-09 Cepheid Métodos de diagnóstico de tuberculose e de diferenciação entre tuberculose ativa e latente
CN116635538A (zh) * 2021-10-22 2023-08-22 塞弗德公司 诊断和治疗结核病的组合物和方法

Also Published As

Publication number Publication date
WO2022076428A1 (en) 2022-04-14
EP4226158A1 (en) 2023-08-16
US20220106627A1 (en) 2022-04-07
CN116348767A (zh) 2023-06-27
KR20230080458A (ko) 2023-06-07

Similar Documents

Publication Publication Date Title
BR112023006262A2 (pt) Métodos de diagnóstico de tuberculose e de diferenciação entre tuberculose ativa e latente
Jia et al. Human infection with Candidatus Rickettsia tarasevichiae
Sharma et al. Multidrug-resistant tuberculosis
Phillips et al. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease
Bradley et al. Clinical efficacy of the amplified Mycobacterium tuberculosis direct test for the diagnosis of pulmonary tuberculosis.
Day et al. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa
Doern et al. A comprehensive update on the problem of blood culture contamination and a discussion of methods for addressing the problem
Bayona et al. Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis
Castro et al. Detection of Treponema pallidum sp. pallidum DNA in cerebrospinal fluid (CSF) by two PCR techniques
Eells et al. Non-suppurative cellulitis: risk factors and its association with Staphylococcus aureus colonization in an area of endemic community-associated methicillin-resistant S. aureus infections
Boggild et al. Diagnostic performance of filter paper lesion impression PCR for secondarily infected ulcers and nonulcerative lesions caused by cutaneous leishmaniasis
Takahashi et al. Pneumocystis carinii carriage in immunocompromised patients with and without human immunodeficiency virus infection
Hargreaves et al. Pneumocystis carinii pneumonia in patients being registered for smear-negative pulmonary tuberculosis in Malawi
Farhat et al. Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment
Ogawa et al. Rat-bite fever in human with Streptobacillus notomytis infection, Japan
Khawcharoenporn et al. Isoniazid preventive therapy and 4-year incidence of pulmonary tuberculosis among HIV-infected Thai patients
Supsrisunjai et al. Case report: Disseminated autochthonous dermal leishmaniasis caused by Leishmania siamensis (PCM2 Trang) in a patient from central Thailand infected with human immunodeficiency virus
Limmathurotsakul et al. Repeat blood culture positive for B. pseudomallei indicates an increased risk of death from melioidosis
van der Heijden et al. Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death
Toh et al. A 5-year retrospective study of melioidosis cases treated in a district specialist hospital
Singh et al. Detecting aerobic bacterial diversity in patients with diabetic foot wounds using ERIC-PCR: a preliminary communication
Sauzullo et al. Interferon-γ release assay in HIV-infected patients with active tuberculosis: impact of antituberculous drugs on host immune response
Kano Carbapenem-Resistant Enterobacteriaceae (CRE) in Intensive Care Units and surgical wards of hospitals with no history of carbapenem usage in Kano, North West Nigeria
Abu Raya et al. The laboratory diagnosis of Bordetella pertussis infection: a comparison of semi-nested PCR and real-time PCR with culture
Rabahi et al. Characterization of Mycobacterium tuberculosis var. africanum isolated from a patient with pulmonary tuberculosis in Brazil